Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis

医学 红斑 脂溢性皮炎 中止 头皮 临床试验 物理疗法 内科学 外科 皮肤病科
作者
Matthew Zirwas,Zoe Draelos,Janet DuBois,Leon Kircik,Angela Moore,Linda Stein Gold,Javier Alonso‐Llamazares,Michael Bukhalo,Suzanne Bruce,Kimmie Eads,Lawrence J. Green,Scott Guenthner,Laura K. Ferris,Seth Forman,Steven Kempers,Edward Lain,Charles Lynde,David M. Pariser,Darryl Toth,Paul S. Yamauchi,Robert Higham,David Krupa,Patrick Burnett,David R. Berk
出处
期刊:JAMA Dermatology [American Medical Association]
卷期号:159 (6): 613-613 被引量:13
标识
DOI:10.1001/jamadermatol.2023.0846
摘要

Importance Current topical treatment options for seborrheic dermatitis are limited by efficacy and/or safety. Objective To assess safety and efficacy of roflumilast foam, 0.3%, in adult patients with seborrheic dermatitis affecting the scalp, face, and/or trunk. Design, Setting, and Participants This multicenter (24 sites in the US and Canada) phase 2a, parallel group, double-blind, vehicle-controlled clinical trial was conducted between November 12, 2019, and August 21, 2020. Participants were adult (aged ≥18 years) patients with a clinical diagnosis of seborrheic dermatitis for a 3-month or longer duration and Investigator Global Assessment (IGA) score of 3 or greater (at least moderate), affecting 20% or less body surface area, including scalp, face, trunk, and/or intertriginous areas. Data analysis was performed from September to October 2020. Interventions Once-daily roflumilast foam, 0.3% (n = 154), or vehicle foam (n = 72) for 8 weeks. Main Outcomes and Measures The main outcome was IGA success, defined as achievement of IGA score of clear or almost clear plus 2-grade improvement from baseline, at week 8. Secondary outcomes included IGA success at weeks 2 and 4; achievement of erythema score of 0 or 1 plus 2-grade improvement from baseline at weeks 2, 4, and 8; achievement of scaling score of 0 or 1 plus 2-grade improvement from baseline at weeks 2, 4, and 8; change in Worst Itch Numeric Rating Scale (WI-NRS) score from baseline; and WI-NRS success, defined as achievement of 4-point or greater WI-NRS score improvement in patients with baseline WI-NRS score of 4 or greater. Safety and tolerability were also assessed. Results A total of 226 patients (mean [SD] age, 44.9 [16.8] years; 116 men, 110 women) were randomized to roflumilast foam (n = 154) or vehicle foam (n = 72). At week 8, 104 (73.8%) roflumilast-treated patients achieved IGA success compared with 27 (40.9%) in the vehicle group ( P < .001). Roflumilast-treated patients had statistically significantly higher rates of IGA success vs vehicle at week 2, the first time point assessed. Mean (SD) reductions (improvements) on the WI-NRS at week 8 were 59.3% (52.5%) vs 36.6% (42.2%) in the roflumilast and vehicle groups, respectively ( P < .001). Roflumilast was well tolerated, with the rate of adverse events similar to that of the vehicle foam. Conclusions and Relevance The results from this phase 2a randomized clinical trial of once-daily roflumilast foam, 0.3%, demonstrated favorable efficacy, safety, and local tolerability in the treatment of erythema, scaling, and itch caused by seborrheic dermatitis, supporting further investigation as a nonsteroidal topical treatment. Trial Registration ClinicalTrials.gov Identifier: NCT04091646
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
顺利兰发布了新的文献求助10
刚刚
Milou完成签到,获得积分20
刚刚
无花果应助沂静采纳,获得10
1秒前
1秒前
1秒前
情怀应助不要引力采纳,获得10
1秒前
2秒前
扬帆起航行万里完成签到,获得积分10
2秒前
happy发布了新的文献求助10
2秒前
3秒前
3秒前
明明明发布了新的文献求助10
3秒前
3秒前
3秒前
沐mu完成签到,获得积分10
4秒前
呱呱呱发布了新的文献求助10
5秒前
窦窦窦窦窦完成签到,获得积分10
5秒前
6秒前
Mutsu应助认真的灵竹采纳,获得20
6秒前
英姑应助LYDZ1采纳,获得10
7秒前
7秒前
8秒前
8秒前
憨人发布了新的文献求助10
8秒前
等风来发布了新的文献求助10
8秒前
9秒前
海北完成签到 ,获得积分10
9秒前
Yang发布了新的文献求助10
9秒前
yu完成签到,获得积分10
10秒前
10秒前
10秒前
10秒前
11秒前
Milou发布了新的文献求助10
11秒前
yellow完成签到,获得积分10
11秒前
蘇q完成签到 ,获得积分10
11秒前
12秒前
诚心青雪发布了新的文献求助10
12秒前
米兰发布了新的文献求助10
13秒前
14秒前
高分求助中
Sustainability in ’Tides Chemistry 2000
Sustainability in ’Tides Chemistry 1500
The ACS Guide to Scholarly Communication 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Handbook of the Mammals of the World – Volume 3: Primates 805
Ethnicities: Media, Health, and Coping 800
Photosynthesis III 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3071500
求助须知:如何正确求助?哪些是违规求助? 2725527
关于积分的说明 7489890
捐赠科研通 2372698
什么是DOI,文献DOI怎么找? 1258220
科研通“疑难数据库(出版商)”最低求助积分说明 610233
版权声明 596916